Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.
1 - 7 . (Canceled without prejudice)
8 . A method of preventing dermatitis in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.
9 . The method of claim 8 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixtures thereof.
10 - 13 . (Canceled without prejudice)
14 . A method of preventing allergic rhinitis in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.
15 . The method of claim 14 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonists, or a mixtures thereof.
16 - 19 . (Canceled without prejudice)
20 . A method of preventing inflammation in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.
21 . The method of claim 20 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixture thereof.
22 - 25 . (Canceled without prejudice)
26 . A method of preventing a condition responsive to leukotriene inhibition which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.
27 . The method of claim 26 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixture thereof.
28 - 31 . (Canceled without prejudice)
32 . The method of claim 26 wherein the condition responsive to leukotriene inhibition comprises asthma or a symptom thereof.
33 . The method of claim 26 wherein the condition responsive to leukotriene inhibition comprises an allergic condition.
34 . The method of claim 26 wherein the condition responsive to leukotriene inhibition comprises inflammation.
35 - 44 . (Canceled without prejudice)
45 . A pharmaceutical composition which comprises:
(a) a therapeutically effective amount of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof;
(b) a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, and a leukotriene receptor antagonist, and or a mixture thereof, and
(c) a pharmaceutically acceptable carrier or excipient.
46 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 2 mg to about 100 mg of leukotriene receptor antagonist, or a pharmaceutically acceptable salt thereof.
47 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 20 mg to about 2500 mg of 5-lipoxygenase inhibitor, or a pharmaceutically acceptable salt thereof.
48 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 20 mg to about 2500 mg of 5-lipoxygenase activating protein antagonist, or a pharmaceutically acceptable salt thereof.
49 . The pharmaceutical composition of claim 45 which further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.
50 - 52 . (Canceled without prejudice)